CCR2 and cancer: Notably, rapamycin treatment not only downregulated CCR2 protein expression (Fig. 7B and Supplementary Fig. S7B) but also restricted the migration of TEMs toward cancer cells (Fig. 7E and Supplementary Fig. S7D), suggesting the potential involvement of mTORC1 signaling in CCR2-mediated macrophage migration.